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Recent advances in technology, including high resolution crystal structures of 
opioid receptors, novel chemical tools, and new genetic approaches have pro-
vided an unparalleled palette of tools for deconstructing opioid receptor actions in 
vitro and in vivo. Here we provide a brief description of our understanding of opioid 
receptor function from both molecular and atomic perspectives, as well as their 
role in neural circuits in vivo. We then show how insights into the molecular details 
of opioid actions can facilitate the creation of functionally selective (biased) and 
photoswitchable opioid ligands. Finally, we describe how newly engineered 
opioid receptor-based chemogenetic and optogenetic tools, and new mouse 
lines, are expanding and transforming our understanding of opioid function and, 
perhaps, paving the way for new therapeutics.
New Insights into the Structure and Function of Opioid Receptors Facilitate 
Small Molecule and Chemogenetic Technologies
Although the historical aspects of opioid receptor science have been extensively summarized 
[1,2], it is helpful to consider that three major classes of classical opioid receptors – m, d, k – were 
originally identified via both pharmacological and radioligand binding approaches, without any 
insights into their molecular structure (see, for example, [3–5]). Parenthetically, it is useful to 
consider that, prior to the molecular cloning of the four known major opioid receptor subtypes 
[6–9], some had even suggested that opioid receptors might not be proteins but rather 
cerebroside sulfate (see [10] for example).
It was with some excitement then that the inactive state structures of all four known mammalian 
opioid receptors were reported in 2012. Thus, the structures of the mouse m [11], human k [12], 
mouse d [13], and human nociceptin (NOP) [14] receptors appeared in the same issue of Nature. 
Both the authors of the structural elucidation studies (see [11–14]) and others [15,16] have 
predicted that these new structures will accelerate structure-guided drug discovery. To date, 
modest successes have been reported for structure-guided drug discovery of new NOP [17] 
and k-opioid receptor (KOR) [18] ligands, providing new chemotypes with modest potency. 
Additionally, nM potency, selective m-opioid receptor (MOR) G-protein-biased agonists of novel 
chemotypes from structure-based screens in silico have been reported (A. Manglik et al., 
unpublished). Given these initial successes, continuing and expanding these structure-guided 
approaches could provide many new opioid receptor ligands with greater therapeutic potential 
and reduced side effects (A. Manglik et al., unpublished).
Structural elucidation of opioid receptors – as might be expected – has also been useful for 
identifying potential modes by which ligands bind to multiple receptors. Thus, for instance, site-
directed mutagenesis and structure-guided docking studies have provided novel insights into 
KOR binding for both conventional and novel agonists and antagonists [19]. These studies have
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Chemogenetics: the term has been
used to describe the processes by
which macromolecules (proteins such
as receptors) can be engineered to
interact with previously unrecognized
small molecules. Designer Receptors
Exclusively Activated by Designer
Drugs (DREADDs) are a commonly
used example in which GPCRs have
been engineered to respond to inert
ligands CNO or salvinorin B.
Cre-recombinase: is an enzyme
derived from the P1 bacteriophage.
The enzyme is a member of the
integrase family of site-specific
recombinases and it is known to
catalyze the site-specific
recombination event between two
DNA recognition sites (loxP sites). This
34 base pair (bp) loxP recognition site
consists of two 13 bp palindromic
sequences flanking an 8 bp spacer
region. The products of Cre-mediated
recombination at loxP sites are
dependent upon the location and
relative orientation of the loxP sites.
DREADD: Designer Receptors
Exclusively Activated by Designer
Drugs represent a typical GPCR-
based chemogenetic tool.
FLP-recombinase: similar to cre, is
a site-directed recombination
technology, to manipulate an
organism's DNA under controlled
conditions in vivo. It is analogous to
Cre-lox recombination, but involves
the recombination of sequences
between short flippase recognition
target (FRT) sites by the recombinase
(Flp)-derived from the 2 mm plasmid
of baker's yeast.
Optogenetics: a technique that
involves the use of light to control
cells in living tissue, typically neurons,
which have been genetically modified
to express light-sensitive proteins.
Opto-XR: based on the wording of
Har Gobind Khorana and others,
chimeric GPCRs have been
developed that replace the
intracellular loops of bovine rhodopsin
with specific intracellular components




methods to engage biological
processes. One utilizes an uncaging
process to make a compound
biologically active in response to light;
the other uses light-sensitive proteins
such as rhodopsin that can excite,























Figure 1. Identification of G-Protein- and b-Arrestin-Biased k-Opioid Agonists. (A) Molecular model of docking 
pose of U69593 to k-opioid receptor (KOR) and structures of U69593 and ICI199441. ICI199441 was identified as a b-
arrestin-biased agonist. (B) Docking pose of salvinorin A to KOR, structure of salvinorin A, and RB-64. RB-64 was identified 
as a G-protein-biased KOR agonist. (C) Salvinorin A shows all of the prototypical actions of KOR agonists in wild-type (WT) 
mice although certain side effects (sedation, impaired coordination, and anhedonia) are reduced in b-arrestin2 knockout 
(KO) mice. RB-64 has analgesic actions and mildly impairs coordination, but is apparently devoid of anhedonia and sedation 
in WT mice. RB-64 has no effect in KOR KO mice, indicating its effects are likely due to KOR agonists.
revealed that different chemotypes likely adopt different poses in the KOR binding pocket. 
Arylacetamides such as U69593 (Figure 1A) and diterpenes such as salvinorin A (Figure 1B) are
predicted to adopt both distinct and overlapping binding modes in KOR [19]. Indeed, it is clear 
that salvinorin A, for instance, differs from all other KOR agonists in that its binding is not 
dependent upon a strong ionic interaction with the highly conserved aspartic acid in transmem-
brane domain III (TMIII; Figure 1B) [19].
Functionally Selective Opioid Ligands
Based on their predicted different binding poses one might suppose that salvinorin A and 
U69593 might display different functional selectivity [20] or biased signaling [21]. However, both 
U69593 (Figure 1A) and salvinorin A (Figure 1B) appear to be balanced human (hKOR) agonists
in vitro. By contrast, a comprehensive screen of KOR agonists and other known drugs and drug-
like compounds revealed that the arylacetamide ICI199441 displays a modest degree of
b-arrestin bias (Figure 1A), while the salvinorin A derivative RB-64 represents a highly 
G-protein-biased agonist in vitro (Figure 1B; [22]). Determining the structural features responsi-
ble for biased signaling at KOR and other opioid receptors would, obviously, be transformative
for structure-based design of functionally selective ligands.
Given that previous studies revealed that RB-64 is active in vivo [23], the authors comprehen-
sively studied the actions of RB-64 compared with reference KOR agonists to clarify the role(s) of
G protein versus b-arrestin-ergic signaling in mice. Initial studies indicated that RB-64 has
psychotomimetic-like activity [23] in that it disrupted the prepulse inhibition of startle response,
which is widely used to predict psychotomimetic actions of drugs [24]. Next, studies in wild-type
(WT) and b-arrestin2 (bARR2) knockout (KO) mice revealed that the analgesic effects of the
balanced KOR agonists U69593 and salvinorin A as well as the G-protein-biased agonist RB-64
were unaffected by b-arrestin2 gene disruption [25,26], suggesting that KOR analgesia was due
at least in part to G protein signaling. Similar results were recently reported for KOR-mediated
inhibition of pruritus [27]. Thus, a G-protein-biased agonist of a different chemotype – iso-
quinolinone 2.1 – was as effective as the balanced agonist U50488H for the inhibition of pruritus
[27]. These findings are broadly supportive of previous studies performed with balanced KOR
agonists [28], suggesting that analgesic actions of KOR agonists might be mediated by
canonical G protein signaling (Figure 1C).
KOR agonists, in addition to their analgesic [29] and psychotomimetic actions [29–32], are
sedative [3], aversive [33], impair coordination [3], and induce dysphoria [31] and anhedonia
[28,34]. Significantly, the G-protein-biased agonist RB-64 displayed a slower onset and decline
of analgesia when compared with salvinorin A – as might be predicted based on its weak activity
at arrestin-ergic signaling as arrestin ‘arrests’ or inhibits G protein signaling of G-protein-coupled
receptors (GPCRs) [35,36]. Thus, 30 min following administration, mice treated with RB-64 still
displayed an analgesic response, while mice treated with U69593 and salvinorin A did not.
RB-64 had no effect in a model of anhedonia, although it did induce conditioned place aversion
in both WT and bARR2 KO mice [25]. RB-64 had little effect on locomotion in the open field and
treated mice showed a lower degree of motoric coordination – similar to results obtained for
salvinorin A in bArrestin2 KO mice. Taken together, these results [25,27] support the notion that
G-protein-biased KOR agonists might represent novel analgesic agents with a reduced side
effect profile when compared with balanced, centrally active KOR agonists. Additionally, as
differences in signaling bias are but one explanation for these findings, further studies with more
highly biased compounds having good drug-like properties are needed to fully test this
hypothesis.
High Resolution Structures of Opioid Receptors and Relevance for Chemogenetics
Recently, a high resolution structure of a nanobody stabilized state of the mouse MOR was
reported, along with biochemical and molecular dynamics simulations of the MOR activation
process [37,38]. Nanobodies are single chain antibodies that are increasingly used in GPCR
structural biology to stabilize various active states [39]. Additionally, the highest resolution
structure to date for any opioid receptor (1.8 Å) was reported for the inactive state of d-opioid
receptor (DOR) [40]. Further, the first x-ray crystallographic [41] and NMR-based [42] structures
of peptides in complex with opioid receptors have been recently reported. Not surprisingly,
global conformational changes are evident when comparing the nanobody stabilized confor-
mation of MOR with the inactive state [37,38]. These are similar to those that have been seen
previously when comparing nanobody stabilized active and inactive states of b2-adrenergic
[43,44] and M2 muscarinic [45] receptors. Of note, the highly conserved sodium ion site, which
stabilizes the inactive state of many GPCRs (Figure 2A,B) [46–49] has disappeared in the active
state of MOR (Figure 2D), although it is predicted to occur in the inactive MOR state (Figure 2C).
Sodium ions have been demonstrated as negative allosteric modulators for opioid receptors in
situ [50,51], as well as cloned and purified opioid receptors in vitro [40].
Using the high resolution structure of KOR, along with comprehensive mutagenesis and molecular
modeling [19,52], the authors predicted that salvinorin B – an inactive metabolite of salvinorin
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Figure 2. Molecular Insights into Opioid Receptor Actions Yield Structure-Based Design of New DREADD. (A, 
B) Overview and close-up view of the sodium (Na+) site in the d-opioid receptor [40]. In (B) residues are numbered according 
to the Ballesteros–Weinstein convention [95]. Panel (C) shows the putative location of the Na+ site in the inactive state of the
m-opioid receptor [11], while (D) shows structural rearrangements leading to the loss of this site in the activated and 
presumably G-protein-coupled state [37]. Panel (E) shows docking results for salvinorin B – an inactive metabolite of 
salvinorin A to the wild-type k-opioid receptor [52]. Panel (F) shows how salvinorin B is predicted to interact with the D3.32N 
mutant opioid receptor, the k-opioid DREADD (KORD). Abbreviation: DREADD, Designer Receptors Exclusively Activated 
by Designer Drugs.
given the ubiquitous nature of the interaction of D138 with basic nitrogen seen in all endogenous
opioid peptides – and as predicted by structural studies [41,42] – the authors anticipated that the
D138N mutation would also be insensitive to opioid peptides as well as non-peptide KOR 
agonists.
Thus, not only did the D138N hKOR mutant receptor show enhanced affinity for salvinorin B but it
was also insensitive to all tested opioid peptides and nitrogen-containing non-peptide
agonists [52].
Given that the D138N mutant could be activated by the inactive KOR ligand salvinorin B, it was
dubbed k-opioid receptor DREADD (see Glossary) (Designer Receptor Exclusively Activated by
Designer Drug [53]) or KORD [52]. Several reports have now demonstrated that KORD silences
neurons in vivo and that this silencing affects behaviors in a manner consistent with neuronal
silencing [52,54,55]. Additionally, as KORD is activated by salvinorin B, it can be used in
combination with the clozapine-N-oxide (CNO)-based DREADDs [53,56] for the multiplexed
chemogenetic modulation of signaling and behavior [52,57]. Thus, based on high resolution
structures of KOR, a new DREADD-based chemogenetic tool has been developed that should
be broadly useful for interrogating neural circuits and signaling.
Optogenetic Tools for Simulating Opioid Signaling In Vitro and In Vivo
The field of optogenetic innovation has been growing rapidly, with most of the efforts by protein
engineers focused on developing novel channel opsins, with shifted kinetics, on/off rates, or ion
filters [58–60]. However, a few groups, including our own, have been working to develop and
characterize GPCR versions of optogenetic tools, which would allow for spatiotemporal engage-
ment of opioid signaling in vitro and in vivo [61–64]. Capitalizing on these recent efforts via
molecular modeling in iTASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/), the
authors generated a chimeric receptor that contains the intracellular components (loops and
C terminus) of the rat MOR fused to the hydrophobic and extracellular components of the rat
rhodopsin receptor [62]. Our goal was to design and implement a photosensitive MOR-like
receptor that responds to light-based stimulation by signaling to intracellular pathways with the
same properties of its WT counterpart. In this report [62], the authors demonstrated that
photostimulation results in canonical MOR signaling as measured by inhibition of cyclic AMP
production, receptor desensitization, coupling to G-protein-coupled inwardly rectifying potas-
sium (GIRK) channels, activation of mitogen-activated protein kinase cascades, and receptor
internalization. Furthermore, using this approach combined with cre-loxP mouse genetic
approaches, the authors expressed an AAV5–opto-MOR–YFP receptor in GABAergic neurons
of the ventral tegmental area (VTA) and found that photostimulation of this pathway was
rewarding, due to an opioid-like disinhibition of GABAergic tone [65,66]. Other recent reports
have used expression of both adrenergic and serotoninergic rhodopsin-like opto-GPCRs in
structures including the dorsal raphe and basolateral amygdala to regulate anxiety behavior
[61,64,67]. Taken together, these results suggest new versions of the opto-MOR, or other
opioid receptor rhodopsin chimeric approaches, could facilitate the millisecond control of
opioid signaling, and thereby elucidate its relevance for temporally precise behaviors in defined
circuits.
Additionally, the results obtained with opto-MOR [62], along with those obtained with the KOR–
DREADD [52], highlight the potential to engage multiple opioid receptor signaling pathways in
the same cell type. Given that many of these receptors are coexpressed, these new tools may
provide a multiplexed method for dissecting receptor interactions, signaling, and circuit level
effects in vitro and in vivo. Future studies are warranted to determine how opto-opioid-like
receptors function in peripheral circuits, and whether they can be further mutated or enhanced to
better mimic endogenous opioid receptor function, as well as to better dissect the role of biased
opioid receptor signaling in vivo with spatiotemporal control [28,68,69].
Optopharmacology for Engaging Opioid Receptor Signaling with
Spatiotemporal Precision
Another useful advance in optical control of opioid receptor function is the recent development of
photoswitchable opioid small molecules and neuropeptides. Key questions for investigating
opioid receptors and their endogenous neuropeptides are ‘how, where, and when’ endogenous 
peptides act within intact neural circuits. To begin to dissect this, the research teams of Bernardo 
Sabatini and John T. Williams, led by efforts of Matthew Banghart and others [70], have 
developed two opioid agonist peptide analogs: [Leu5]-enkephalin (CYLE) and the eight amino 
acid form of Dynorphin A (CYDyn-8). These analogs contain a modified N-terminal carboxyni-
trobenzyl (CNB) chromophore, which is released at a high quantum efficiency upon photolysis. 
Importantly, these modified peptides are inert and functionally inactive in the absence of 
photolysis. However, when exposed to a pulse of UV light (405 nm), they become functional 
and may then activate endogenous opioid receptors. Banghart and Sabatini [70] have shown 
robust in vitro data, demonstrating m-opioid receptor-coupled GIRK channel coupling, suggest-
ing that these compounds can be used reliably for dissecting MOR function.
Furthermore, small molecule photoswitchable opioid ligands have also been developed that can 
act to antagonize endogenous or exogenous opioid receptor agonists in vitro [71]. Carboxyni-
troveratryl-naloxone (CNV-NLX) was generated as a caged analog of the competitive opioid 
receptor antagonist naloxone (NLX). The authors [71] investigated its utility in both HEK cell and 
slice preparations. They reported that CNV-NLX, with dermorphin as the agonist, can block 
opioid receptor-mediated GIRK channel coupling after photo-uncaging. Interestingly, in this 
report the authors were able to utilize this novel tool to demonstrate that some MOR agonists 
have alternate deactivation rates, which are governed by their G protein signaling, yet others are 
determined by agonist dissociation rate. In an elegant complementary study, using CYLE with 
CNV-NLX, two different alterations in opioid signaling were determined in MOR desensitization 
within locus coeruleus neurons [72]. The author concludes that opioid receptor desensitization is 
both a reduction in ‘active’ receptor number as well as a decrease in agonist receptor affinity of 
the remaining receptor pool. The rapid spatiotemporal control of opioid ligands using photo-
uncaging affords the investigator the ability to assess kinetics of association and dissociation. 
Further, photo-uncaging could reveal how quickly receptor-induced signaling activation/deac-
tivation follows following receptor occupancy by ligand. These approaches are powerful addi-
tions to the opioid receptor tool box in vitro, and perhaps could eventually be used for behavioral 
and systems level experiments in vivo. In vivo photopharmacology has been a significant 
challenge because delivery of UV light to deep brain structures, along with pharmacological 
infusion is technically challenging, although new wireless devices that can co-deliver light and 
drug simultaneously may be promising in this respect [73]. In this recent report, delivery of 
opioids (DAMGO) was demonstrated using a microfluidic probe. Extensions of this technology 
using UV LEDs or other photoswitchable ligands could transform our understanding of the 
relationships between opioid ligands and receptor activity within the spatiotemporal framework 
of intact neural circuits [73].
Rodent Genetic Tools for Dissecting Opioid Receptor Function In Vivo
Over the past decade one of the most useful animal tools utilized in the opioid field has been KO 
mice of both opioid receptors (MOR, KOR, DOR, and NOP) and peptides (proopiomelanocortin, 
enkephalin, preprodynorphin, prepronociceptin) [74–79]. These global KO mice have provided a 
clearer picture of the role of opioid receptors and their endogenous ligands in behavioral models 
of pain, analgesia, stress, depression, and anxiety [74–79]. More recently, conditional deletion 
approaches have been developed wherein loxP sites have been introduced flanking various 
opioid receptor exons, to utilize the power of cell type selective cre-recombinase strategies for 
selective gene deletion within discrete cells and neural circuits [80,81]. Conditional KO mice for 
m-, k-, and d-opioid receptors have been developed. Initial experiments reveal discrete roles for 
individual neuronal populations and specific opioid receptor subtype expression [80–82]. These 
mice have just become more widely available to the research community, and thus it is expected 
that future studies using them will reveal novel insights into receptor function within specific 
neural circuits.
Additional intersectional (e.g., using FLP-recombinase) viral and knock-in approaches may
further provide a powerful tool set for dissecting the functions of subsets of neurons
expressing opioid receptors and their ligands [83–85]. A recent example showed that
selective deletion of KOR from dopamine neurons (DATcre+) has anxiolytic-like properties
and alters cocaine-induced plasticity [81]. In a complementary study, Ehrich and colleagues
showed the rescue of KOR in KOR KO mice (using a new Cre-dependent KOR virus) only in
DATcre+ cells restores KOR-mediated conditioned place aversion [86]. These types of
experiments highlight both the genetic specificity and defined neural circuit contributions
of distinct opioid receptors.
Rodent Genetic Tools for Dissecting the Roles of Opioid Peptides In Vivo
Extending these conditional approaches for examining receptor function within discrete cell types
have been efforts to develop conditional KO mice for each endogenous opioid peptide, along with
Cre-driver mice for each, so that neurons containing these peptides can be targeted using
chemogenetic and optogenetic approaches [56] (Figure 3). Conditional KO mice for proopiome-
lanocortin, proenkephalin, and prodynorphin have each been developed and are in the initial
testing phases for viability and phenotyping [87–89]. Since each of these prepropeptides generate
a multiplicity of active peptide species, deleting the precursors will result in the deletion of many
active peptides. Viral cre-recombinase or INTERSECT [85] approaches are likely to have important
implications when isolating the contributions of these neuropeptides to behavioral systems level
questions. In parallel, cre-driver mice of each opioid peptide will become more widely available.
These will allow for expression of opto- and chemogenetic actuators in neurons expressing opioid
peptides. Such Cre-driver mice would be useful for dissecting the role of endogenous opioid tone,
circuit-based opioid receptor function, how opioids are released, and whether there are promis-
cuous opioid peptide–receptor interactions, as have been hypothesized and suggested over the
past several years. Finally, several laboratories are also developing receptor-based cre-driver mice
(NOP-cre, MOR-cre, KOR-cre, DOR-cre) for isolating populations of cells that express opioid
receptors.
Recent efforts have begun to use dynorphin-cre driver mice [87,88] in both chemogenetic and
optogenetic experiments to define the endogenous nature of dynorphinergic tone on feeding
behavior, reward, and aversion. The surprising findings thus far include the observation of
optogenetically evoked opioid neuropeptide release after relatively mild stimulation, as well as
noncanonical roles for k-opioid-mediated behavioral effects [87] (Figure 3). By contrast, proo-
piomelanocortin-cre driver animals have been useful for targeting the arcuate nucleus and
hippocampus [90], yet little is known about whether these neurons can be evoked to release
proendorphin, the endogenous MOR agonist, in an activity-dependent manner. Enkephalin-cre
driver mice have recently been generated by the Allen Brain Institute, and are likely to be
widely used in studies of basal ganglia function, as well as in reward neurobiology and
neuropharmacology.
Finally, targeted GFP–, YFP–, and mCherry–opioid receptor fusion mice are now being used to
examine endogenous receptor localization, trafficking, and expression [91–93]. Owing to the
constraints and limitations of opioid receptor antibodies, these mice have proven useful in
determining the localization and kinetics of receptors within specific neuronal cell types. In
particular, recent efforts using MOR–mCherry and DOR–eGFP have determined that these
receptors are expressed in distinct but overlapping populations dependent on the cell type and
location. Furthermore, findings in NOP–eGFP mice were recently published [91], and it was
revealed that this receptor is expressed in a subpopulation of dorsal root ganglion neurons.
Additionally, initial and intriguing data were reported on internalization properties of NOP within
endogenous neuronal cultures [91]. These types of receptor fusion fluorophore approaches do
come with caveats, given that the GFP/mCherry tag could interfere with receptor trafficking and
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Figure 3. Summary of Modern Optogenetic Approaches for Dissecting Opioid Peptide and Receptor 
Function In Vitro and In Vivo. (A) Cartoon depicting chimeric ‘Opto-XR’ approach in which rhodopsin cDNA is fused 
with wild-type G-protein-coupled receptor (GPCR) cDNA intracellular loops and tail to generate a photosensitive receptor 
system capable of spatiotemporal engagement of canonical GPCR signaling pathways such as Gq, Gs, and Gi or arrestin 
recruitment in selected cell types when combined with viral and genetic approaches in vivo. Opto-MOR receptors [62] take 
advantage of similarities between RO4 Gi coupled opsins and m-opioid receptors. (B) Left, One-letter amino acid sequences 
of LE, Dyn-8, and their corresponding photoswitchable CNB-modified analogs CYLE and CYD8. Right, The chemical 
structure of CYLE. The CNB moiety (photoswitch) is highlighted in red. Adapted from [70]. (C) Summary of circuit-based 
chemogenetic and optogenetic targeting approach and available endogenous opioid cre-driver mice. Strategy is provided 
using a double-inverted open reading frame (DIO) construct, and fiber optics for optogenetic manipulation. For DREADD-
based approaches, injection and then CNO manipulations would occur in vivo or in vitro. Extensions of this approach are 
also possible, whereby other opsins or DREADDs can be used for multiplexing or inhibition experiments. Abbreviations: 
CNB, carboxynitrobenzyl; CNO, clozapine-N-oxide; CYLE, [Leu5]-enkephalin; DREADD, Designer Receptors Exclusively 
Activated by Designer Drugs; Dyn-8, eight amino acid form of Dynorphin A; MOR, m-opioid receptor.
function. Additionally, background fluorescence can impede rigorous conclusions about sub-
cellular localization of fusion proteins. Nevertheless, taken together with the other approaches
described earlier, they provide another novel avenue of resolution that reveals how and where
opioid receptors are functional within intact neuronal circuits.
Concluding Remarks
In summary, we have outlined some of the recent advances in technology that have allowed for a
deeper and more rigorous understanding of opioid receptor neurobiology and pharmacology.
We have by no means provided a comprehensive survey of this rapidly progressing field, but
instead we have focused on some of the emerging techniques, tools, and approaches, which
have the potential to unravel historically critical mysteries in the field (see Outstanding Questions).
Clearly, improvements in high resolution structural determination of opioid receptors and
complexes via crystallography along with enhanced GPCR modeling and docking approaches
[94] will provide powerful templates for the structure-guided discovery of novel opioid receptor
ligands. Additional refinements of both chemogenetics and optogenetics as well as viral delivery
platforms will provide the technologies for resolving long-standing issues related to cell type-
specific actions of opioid ligands and receptors. Finally, development of suitably drug-like and
highly G-protein- and b-arrestin-biased ligands for all four opioid receptors will be extraordinarily
valuable for elucidating the relative roles of canonical versus noncanonical signaling for the many
actions mediated by exogenous and endogenous opioids. Although the field of opioid receptor
pharmacology will always rest on pharmacological methods and concepts for its foundation,
these emerging technologies provide an unparalleled opportunity for addressing key enigmas in
opioid receptor structure and function.
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